Dova Pharmaceuticals Inc. Contracts & Agreements
39 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (7)
- Human Resources (15)
- Intellectual Property (1)
- Mergers & Acquisitions (1)
- Real Estate (3)
- Uncategorized (2)
- Agreement and Plan of Merger, dated as of September 30, 2019, by and among Dova Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ) and Dragonfly Acquisition Corp (Filed With SEC on October 3, 2019)
- Lease amendment, dated as of May 13, 2019, between Dova Pharmaceuticals, Inc. and Pine Forest 240 TT, LLC (Filed With SEC on August 6, 2019)
- First Amendment to the Co-Promotion Agreement, dated June 27, 2019 (Filed With SEC on June 27, 2019)
- Amended and Restated Loan and Security Agreement, dated as of May 6, 2019, by and among Dova Pharmaceuticals, Inc., AkaRx, In., Silicon Valley Bank and WestRiver Innovation... (Filed With SEC on May 7, 2019)
- Employment Agreement, by and between the Company and David S. Zaccardelli, dated as of December 17, 2018 (Filed With SEC on March 5, 2019)
- Employment Agreement, by and between the Company and Jason Hoitt, dated as of December 17, 2018 (Filed With SEC on March 5, 2019)
- Amended and Restated 2017 Equity Incentive Plan, as amended (Filed With SEC on December 20, 2018)
- Form of Restricted Stock Unit Grant Notice and Award Agreement (Filed With SEC on December 20, 2018)
- Second Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on December 20, 2018)
- Co-Promotion Agreement, dated as of September 26, 2018, by and between the Registrant and Valeant Pharmaceuticals North America LLC (Filed With SEC on November 8, 2018)
- Amended and Restated Transition Services Agreement, dated as of April 1, 2018, by and between AkaRx, Inc. and Eisai Inc (Filed With SEC on November 8, 2018)
- Loan and Security Agreement, dated as of April 17, 2018, by and between the Registrant, AkaRx, Inc. and Silicon Valley Bank (Filed With SEC on August 9, 2018)
- Commercial Outsourcing Master Services Agreement, dated as of March 1, 2018, by and between the Registrant and Integrated Commercialization Solutions, LLC, as amended (Filed With SEC on August 9, 2018)
- At-the-Market Equity Offering Sales Agreement, dated July 27, 2018, by and between Dova Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on July 27, 2018)
- Office Lease Agreement, dated May 22, 2018, by and between the Registrant and Pine Forest 240 TT, LLC (Filed With SEC on May 24, 2018)
- Amendment to Services Agreement, by and between the Registrant and PBM Capital Group, LLC, dated as of March 29, 2018 (Filed With SEC on May 9, 2018)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2018)
- Form of Underwriting Agreement (Filed With SEC on February 20, 2018)
- Employment Agreement, by and between the Company and Mark W. Hahn, dated as of January 31, 2018 (Filed With SEC on January 31, 2018)
- Amendment to Sublease, by and between the Registrant and Paidian Research, Inc., dated as of September 22, 2017 (Filed With SEC on November 9, 2017)
- DOVA PHARMACEUTICALS, INC. [] Shares of Common Stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on June 19, 2017)
- DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 14, 2017 APPROVED BY THE STOCKHOLDERS: June 15, 2017 IPO DATE: ,... (Filed With SEC on June 19, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on June 19, 2017)
- SUPPLY AGREEMENT between Eisai Inc. and AkaRx, Inc. Dated as of June 9, 2017 (Filed With SEC on June 9, 2017)
- STOCK PURCHASE AGREEMENT BETWEEN EISAI INC. and PBM AKX HOLDINGS, LLC Dated as of March 29, 2016 (Filed With SEC on June 2, 2017)
- SECURED PROMISSORY NOTE (Filed With SEC on June 2, 2017)
- SECURITY AGREEMENT (Filed With SEC on June 2, 2017)
- GUARANTEE (Filed With SEC on June 2, 2017)
- YM477 LICENSE AGREEMENT (Filed With SEC on June 2, 2017)
- TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and AkaRx, Inc. Dated as of March 30, 2016 (Filed With SEC on June 2, 2017)
- SERVICES AGREEMENT (Filed With SEC on June 2, 2017)
- SERVICES AGREEMENT (Filed With SEC on June 2, 2017)
- INVESTORS RIGHTS AGREEMENT (Filed With SEC on June 2, 2017)
- DOVA PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 28, 2017 APPROVED BY THE STOCKHOLDERS: APRIL 11, 2017 TERMINATION DATE: MARCH 27,... (Filed With SEC on June 2, 2017)
- DOVA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) (Filed With SEC on June 2, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2017)
